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Abstract Tumor budding refers to single or small cluster of
tumor cells detached from the main tumor mass. In colon
cancer high tumor budding is associated with positive lymph
nodes and worse prognosis. Therefore, we investigated the
value of tumor budding as a predictive feature of lymph node
status in breast cancer (BC). Whole tissue sections from 148
surgical resection specimens (SRS) and 99 matched preop-
erative core biopsies (CB) with invasive BC of no special type
were analyzed on one slide stained with pan-cytokeratin. In
SRS, the total number of intratumoral (ITB) and peripheral
tumor buds (PTB) in ten high-power fields (HPF) were
counted. A bud was defined as a single tumor cell or a cluster
of up to five tumor cells. High tumor budding equated to scores
averaging[4 tumor buds across 10HPFs. In CB high tumor
budding was defined as C10 buds/HPF. The results were
correlated with pathological parameters. In SRS high PTB
stratified BC with lymph node metastases (p B 0.03) and
lymphatic invasion (p B 0.015). In CB high tumor budding
was significantly (p = 0.0063) associated with venous
invasion. Pathologists are able, based on morphology, to
categorize BC into a high and low risk groups based in part on
lymph node status. This risk assessment can be easily per-
formed during routine diagnostics and it is time and cost ef-
fective. These results suggest that high PTB is associated with
loco-regional metastasis, highlighting the possibility that this
tumor feature may help in therapeutic decision-making.
Keywords Breast cancer  No special type  Tumor
budding  Vessel invasion  Metastasis
Background
Breast cancer (BC) is considerably heterogeneous both
molecularly and histologically. It is presented as a collection
of distinct disease subtypes that differ in disease progression,
treatment response, and disease-free survival [1–5]. A vari-
ety of clinical pathological and genetic factors are routinely
used to assess prognosis and determine the most appropriate
therapeutic regimen for patients with BC [6, 7]. These in-
clude patient age, axillary lymph node status, tumor size,
histological grade, lymphatic invasion, hormone receptor
status, HER2 status, and evaluation of tumor margins. More
recently, molecular tests such as Oncotype DX and Mam-
maPrint are being utilized to assess likelihood of treatment
response and/or recurrence. However, additional prognosti-
cators are needed to enhance personalized treatment and
especially to overcome over and under treatment of patients.
Despite the substantial molecular and morphological
differences, all invasive BC subtypes likely share a path-
way for invasion, evidenced from morphological changes
that occur in the transition to all invasive carcinomas.
Normal epithelia, including pre-invasive breast cancers
(carcinoma in situ), are physically separated from
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surrounding stroma and vascular structures by a basement
membrane and a layer of myoepithelial cells [3]. Disrup-
tion of this barrier is a pre-requisite for invasion in all
breast cancers. In addition, the invasive front of breast
cancer also includes infiltrates of diverse immune cells
including macrophages, neutrophils, and mast cells, and
displays angiogenesis, and desmoplasia with deposition of
extracellular matrix (ECM), particularly collagen I [8].
In colorectal carcinomas (CRC), morphological studies
of the invasive front have revealed the emergence of tumor
budding, which reflect detachment of tumor cells into
single cells or clusters of up to five cells [9]. Tumor bud-
ding is diagnosed at high magnification and should not be
mistaken with the tumor border configuration, which is
more easily discernable at low magnifications.
Biologically, the role of tumor budding includes a
mechanism for invasive cells to migrate through peri-tu-
moral connective tissue, evade the host’s defensive
mechanisms and invade lymphatic and blood vessels with
the consequence of local and distant metastases [9].
Over the last few years, numerous publications have
shown the importance of tumor budding as an independent
predictor of lymph node positivity, local and distant re-
lapse, lymphatic invasion, and poor prognosis among pa-
tients with CRC of all pathological stages [9]. However,
the definite implementation of tumor budding into clinical
practice is currently limited by the lack of an internation-
ally standardized scoring system. Whether tumor budding
can be considered a histomorphologic features in BC re-
mains to be elucidated. The purpose of the current study
was to evaluate the potential clinical value of tumor bud-
ding in breast cancer of no special type (NST) as a pre-
dictor of lymph node metastasis.
Materials and methods
Patient samples
We searched the database at the Institute of Pathology,
University of Bern, Switzerland for patients diagnosed with
primary BC between January 2005 and December 2011.
We identified 356 patients with suitable formalin fixed and
paraffin-embedded (FFPE) samples from female patients
with therapy naı¨ve, primary, unilateral BC of more than
5 mm in size to construct a next-generation tissue mi-
croarray (ngTMA). From these patients, we selected 148
individual surgical resection specimens (SRS) and 99
matching preoperative core biopsies (CB) from patients
with invasive BC of no special type (NST) and known
lymph node status for tumor budding analysis. The TNM
classification was taken from the pathology reports, and the
clinical data were extracted from the database of the breast
center of the University Hospital Bern, Switzerland. The
median age of selected patients at the time of diagnosis was
61 years (range 32–91 years). The clinico-pathological
features for the sample cohort are summarized in Table 1,
and the study design is presented in Fig. 1.
All BCs were reviewed and the histological subtype and
tumor grade were assigned according to the WHO classi-
fication 2012. The study was approved by the ethical
committee of the University of Bern (Registration
200/2014) and was performed according to the REMARK
guidelines [10]. Long-term follow-up data were not avail-
able for this cohort.
Next-generation tissue microarray (ngTMA)
For the assessment of the prognostic factors, a ngTMA was
constructed including 356 selected BC samples as previ-
ously described [11]. In brief, whole tissue sections of the
tumors were scanned and uploaded to a digital platform to
make annotations for the punching process. The tumor
image on the screen allowed an optimal overview of the
sample for digital annotations of the regions of intersest,
including areas from the tumor center and periphery. The
fully automated arraying process synchronized the anno-
tations made on the scanned slide with the image of the
donor paraffin block to precisely punch the area of interest.
For the majority (97.8 %) of BC samples, six punches of
0.6 mm were integrated into a new recipient block repre-
senting the ngTMA.
Immunohistochemistry (IHC) and fluorescence
in situ hybridization (FISH)
Prior to ngTMA construction, 3 lm whole tissue sections
from one selected FFPE tissue block of the 148 NST BCs
were cut and incubated with an anti-cytokeratin antibody
for better visualization of tumor buds for evaluation.
Estrogen (ER) and progesterone (PgR) receptor, Her2 and
MIB1 were performed on the ngTMA. The antibodies and
the specific conditions used are listed in Table 2.
For ER, PgR, and Her2, the ASCO/CAP guidelines were
applied to define positive hormone receptor and Her2 sta-
tus, respectively [12, 13]. In BC with equivocal immuno-
histochemistry, fluorescence in situ hybridization (FISH)
was performed using a dual-color probe (Abbott Molecular
Abbott Park, Illinois, USA).
The molecular subtypes were defined as follows: Lu-
minal A: estrogen (ER) and/or progesterone receptor (PgR)
positive, Her2 negative, low proliferative index (B15 %);
Luminal B: hormone receptor positive, Her2 positive/or
high proliferative index ([15%); Her2 subtype: Her2
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positive and hormone receptor negative, any proliferative
index; triple negative: Her2 negative, hormone receptor
negative, any proliferative index.
Scoring of tumor buds
Tumor buds were defined as isolated single cancer cells or
microscopic cell clusters composed of 1–5 cells. The
number of buds was counted on whole tissue sections of
surgical resection specimens (SRS; n = 148) and matched
preoperative core biopsies (CB; n = 99) stained with a
pan-cytokeratin antibody (AE1/AE3) for better visualiza-
tion. Areas with the highest concentration of buds (‘‘hot-
spots’’) were selected for scoring. BC samples were se-
lected from the cohort of the ngTMA as described earlier.
In SRS, tumor buds at the invasive front or within the
tumor center were scored separately. Invasive tumor front
buds are referred to as peripheral tumor buds (PTB) and
were scored within &1.1 mm (2 9 1 high-power field
(HPF) @0.55 mm2) on either direction of the tumor in-
terface. Tumor buds within the center are referred to as
intratumoral buds (ITB) (Fig. 2). We used pre-defined
criteria for the assessment of tumor buds in accordance
with recent publications describing scoring of tumor buds
in colon cancer SRS [14] and cut-off criteria in BC [15].
For SRS, 2 pathologists (CT, MT) scored 10 HPF inde-
pendently and blindly without knowledge of tumor char-
acteristics (e.g., nodal status) and each other’s results.
According to a recent report [15], tumors were considered
to have high tumor budding if the average number of tumor
buds in 10 HPF[4. In contrast, tumors were considered to
have low tumor budding if the average number of buds in
10 HPF was B4. Examples of high tumor budding are seen
in Fig. 3 and examples of low tumor budding are given in
Fig. 4.
Since CBs are not easily comparable to SRSs, we per-
formed a receiver operating characteristic (ROC) curve
analysis to find the appropriate cut-off for high and low
tumor budding. In addition, we scored only 1HPF with the
highest density of tumor buds as previously reported for
preoperative colon biopsies [16]. Furthermore, ITB and
PTB cannot be distinguished in CB because they are ran-
domly sampled. One pathologist (CT) scored tumor bud-
ding in all CBs. In all SRSs and CBs tumor buds were
counted at 9400 magnification (0.55 mm2).
Statistics
The Chi Square test was used to calculate significant dif-
ferences between categorical variables. Pearson’s correla-
tion coefficient was used to determine the strength of
the linear relationship between budding in CB and SRS
(ITB and PTB). A p value \ 0.05 was considered statisti-
cally significant. Interrater reliability was calculated with
Cohen’s Kappa test with the following interpretations
for the kappa value 0–0.2 = poor; 0.21–0.4 = fair;
Table 1 Patient characteristics (n = 148)
Feature Frequency N (%)
Age (years) Median (min, max) 61 (32, 91)
Tumor size (cm) Median (min, max) 2.0 (0.6–8.0)
ER Positive 125 (84.5)
Negative 23 (15.5)
PgR Positive 104 (70.3)
Negative 44 (29.7)
Her 2 Positive 19 (12.8)
Negative 129 (87.2)
MIB1 High ([15 %) 40 (27.0)
Low (B15 %) 107 (72.3)
No data 1 (0.7)
Grade G1 18 (12.2)
G2 69 (46.6)
G3 61 (41.2)
pT T1 75 (50.7)
T2 66 (44.6)
T3 3 (2.0)
T4 4 (2.7)
pN pN0 68 (45.9)
[pN0 80 (54.1)
Molecular subtypes Luminal A 92 (62.2)
Luminal B 33 (22.3)
Her2 3 (2.0)
Triple negative 20 (13.5)
Lymphatic invasion No 89 (60.1)
Yes 58 (39.5)
No data 1 (0.7)
Venous invasion No 135 (91.2)
Yes 12 (8.1)
No data 1 (0.7)
Perineural invasion No 128 (86.5)
Yes 19 (12.8)
No data 1 (0.7)
Hormone therapy No 55 (37.2)
Yes 38 (25.7)
Unknown 55 (37.1)
Chemotherapy No 58 (39.2)
Yes 34 (23.0)
Unknown 56 (37.8)
Anti-Her2 therapy No 81 (54.7)
Yes 5 (3.4)
Unknown 62 (41.9)
Radiotherapy No 32 (21.6)
Yes 106 (71.6)
Unknown 10 (6.8)
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0.41–0.6 = moderate; 0.61–0.8 = substantial; [0.8 = ex-
cellent [17]. To calculate a cut-off for high and low tumor
budding in CB, receiver operating characteristic (ROC)
curve analysis was performed. Analyses were carried out
using SPSS 21 (IBM, Armonk, US) and SAS (V9.4, The
SAS Institute, Cary, NC).
Results
A total of 148 surgical resection specimens (SRS) and 99
matching preoperative core biopsies (CB) with invasive
NST BC were evaluated. ER, PgR, Her2, and MIB1 pro-
liferative index were obtained from ngTMA evaluation and
are summarized in Table 1. In two patients, Her2 status
(1.4 %) and in three patients MIB1 (2.0 %) results were
taken from the pathological reports due to insufficient
material present for evaluation on the ngTMA.
The concordance of the two pathologist regarding
scoring of high and low tumor budding was k = 0.526 for
PTB and k = 0.533 for ITB.
Correlation of tumor budding with clinical-
pathological characteristics
Significant associations with PTB in surgical resection
specimens
The individual scores of pathologists showed a significant
correlation of high PTB with positive lymph node status
(p = 0.003 and 0.03) and lymphatic invasion (LVI)
(p = 0.015 and 0.013), respectively. The only significant
result when combining the scoring of both pathologists
was the association of high PTB with lymphatic invasion
(p = 0.029). In addition, analysis of only ER-positive
and low proliferative BCs, respectively, showed the fol-
lowing results: Pathologist 1 showed a significant corre-
lation with lymph node metastasis and high PTB when
analyzing only ER-positive BCs (p = 0.007) and in
samples with low proliferative BCs (p = 0.006), respec-
tively. Pathologist 2 had no significant results for sub-
group analysis and no other significant correlations were
seen for high PTB.
ngTMA
n=356
Surgical resection specimens of NST BC
n=148
Matching preoperative core biopsies
n=99
ngTMA= Next-generation tissue microarray
NST BC= No special type breast cancer
PgR= Progesterone receptor
Her2= Human epidermal growth factor receptor 2
MIB1= Proliferation
PTB= Peripheral tumor budding
ITB= Intratumoral budding
Assessment of: 
ER, PgR, Her2, MIB1
Assessment of: 
PTB and ITB
Assessment of: 
Tumor budding
Fig. 1 Flow chart study
Table 2 Specifications of
immunohistochemistry and
antibodies used
Antibody Clone Cat#/vendor Dilution Retrival
Estrogen receptor EP1 M3643/Dako 1:50 Tris pH 8.4 40 min 95 C
Progesterone receptor 16 SAN27 NCL-L-PGR-AB/Novocastra 1:200 Tris pH 8.4 40 min 95 C
Her2 Poly K5207/Dako Kit citrat pH6 20 min 100 C
MIB1 Mib1 M7240/Dako 1:200 Tris pH 8.4 30 min 95 C
Cytokeratin AE1/AE3 M351501-2/Dako 1:300 Proteinase K 5 min 37 C
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Interface between tumor and stroma= tumor front 
Two high power fields from the interface=peripheral 
>2 high power fields from the interface= central 
Area of PTB 
Area of ITB 
Fig. 2 Peripheral and
intratumoral budding
Fig. 3 NST breast cancer with high tumor budding. Overview (94) of a high PTB (a) and high ITB (c) breast cancer stained with anti-pan-
cytokeratin antibody. b and d A high-power field (940) with more than four tumor buds
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Significant associations with ITB in resection specimens
High ITB scoring results of Pathologist 1 showed a sig-
nificant association with tumor grade (p = 0.036), ER
positivity (p = 0.02) and lower proliferation (p = 0.002).
The scoring results of Pathologist 2 demonstrated a sig-
nificant association with negative Her2 status (p = 0.001)
and perineural invasion (p = 0.039). The scoring results
with significant associations are summarized in Table 3 and
the subgroup analysis of PTB are summarized in Table 4.
Significant associations of tumor budding in preoperative
core biopsies
Ninety-nine patients (66.9 %) with CB were identified
from the 148 SRSs and evaluated for the presence of tumor
budding. A significant positive correlation was found be-
tween budding in the CB and ITB (r = 0.28; p = 0.0045)
and PTB (r = 0.48; p \ 0.0001) of the SRS. In CB, tumor
budding was significantly associated with V classification
(p = 0.0063). All 35 patients with low-grade tumor bud-
ding (\10 buds/HPF) showed no venous invasion while
12/64 (19 %) patients with high-grade budding were di-
agnosed with venous invasion. No other significant
associations were found with other pathological parameters
(Table 4
Discussion
Tumor budding is best described as a histologic pattern asso-
ciated with poor prognosis in early-stage colorectal adeno-
carcinoma and a predictor of nodal metastasis in T1 colorectal
adenocarcinoma [18]. Recently, some of these associations
were also found in esophageal carcinoma and pancreatic
cancer [19, 20]. Therefore, we investigated the significance of
tumor budding and its relationship to known clinico-patho-
logical features of BC such as nodal metastasis, tumor grade,
and tumor size. In this retrospective study, we used a semi-
quantitative histologic scoring system to categorize 148 sur-
gically resected, primary invasive NST BC’s for the extent of
both ITB and PTB. Additionally, 99 matching CBs were
analyzed for tumor budding. We selected invasive ductal BC
because they are the most prevalent histological subtypes [21]
and represent a heterogeneous group with varying tumor fea-
tures including immunphenotypical and clinical outcomes.
Therefore, it would be of great clinical value to find additional
prognostic or predictive tumor features for this group.
Fig. 4 NST breast cancer with low tumor budding. Overview (94) of a low PTB (a) and low ITB (c) breast cancer stained with anti-pan-
cytokeratin antibody. b and d A high-power field (940) with less than four tumor buds
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During the course of our study, a paper was published by
Liang et al. which demonstrated that high-grade budding in
SRS was significantly associated with the presence of
lymphatic invasion (LVI), larger tumor size, and worse
clinical outcome [15]. We confirmed a significant asso-
ciation with LVI (p = 0.029) for PTB. Additionally, both
pathologists were able to stratify BCs with positive lymph
node metastases according to having a high PTB count
(p = 0.004 and 0.03). Liang et al. reported that BC patients
with high tumor bud scores have worse overall survival.
Although long-term follow-up data were not available for
the samples in this study, the association of tumor budding
Table 3 Summary of significant results and tumor budding
Features PTB1 n (%) p-value PTB2 n (%) p-value
Low 30 (20.3) High 118 (79.7) Low 17 (11.5) High 131 (88.5)
pN Positive 9 (11.2) 71 (88.8) 0.003 5 (6.2) 75 (93.8) 0.03
Negative 21 (30.9) 47 (69.1) 12 (17.6) 56 (82.4)
Lymphatic invasion Positive 6 (10.3) 52 (89.7) 0.015 2 (3.4) 56 (96.6) 0.013
Negative 24 (27) 65 (73) 15 (16.9) 74 (83.1)
Features ITB1 n (%) p-value ITB2 n (%) p-value
Low 30 (20.9) High 117 (79.1) Low 24 (16.2) High 124 (83.8)
Grading G1 3 (16.7) 15 (83.3) 2 (11.1) 16 (88.9)
G2 9 (13.0) 60 (87.0) 0.036 9 (13.0) 60 (87.0) 0.364
G3 19 (31.1) 42 (68.9) 13 (21.3) 48 (78.7)
ER Positive 22 (17.6) 103 (82.4) 0.02 19 (15.2) 106 (84.8) 0.434
Negative 9 (39.1) 14 (60.9) 5 (21.7) 18 (78.3)
Her2 Positive 7 (36.8) 12 (63.2) 0.68 8 (42.1) 11 (57.9) 0.001
Negative 24 (18.6) 105 (81.4) 16 (12.4) 113 (87.6)
Molecular subtypes Luminal A 11 (12.0) 81 (88.0) 11 (12.0) 81 (88.0)
Luminal B 11 (33.3) 22 (66.7) 0.007 8 (24.2) 25 (75.8) 0.038
Her2 1 (33.3) 2 (66.7) 2 (66.7) 1 (33.3)
Triple negative 8 (40.0) 12 (60.0) 3 (15.0) 17 (85.0)
MIB1 High ([15 %) 15 (37.5) 25 (62.5) 0.002 9 (22.5) 31 (77.5) 0.216
Low (B15 %) 15 (14.0) 92 (86.0) 15 (14.0) 92 (86.0)
Perineural invasion Positive 1 (5.3) 18 (94.7) 0.7 0 (0.0) 19 (100)
Negative 30 (23.4) 98 (76.6) 24 (18.8) 104 (81.2) 0.039
PTB1 peripheral tumor budding score from Pathologist 1
PTB2 peripheral tumor budding score from Pathologist 2
ITB1 intratumoral budding score from Pathologist 1
ITB2 intratumoral budding score from Pathologist 2
Bold italic significant results
Table 4 Subgroup analysis with significant results
Features PTB1 n (%) p-value PTB2 n (%) p-value
Low High Low High
Only ER positive pN positive 7 (10.8) 58 (89.2) 5 (7.7) 60 (92.3)
pN negative 18 (30.0) 42 (70.0) 0.007 10 (16.7) 50 (83.3) 0.123
Only low MIB1 (B15 %) pN positive 4 (7.5) 49 (92.5) 0.006 3 (5.7) 50 (94.3) 0.194
pN negative 15 (27.8) 39 (72.2) – 7 (13.0) 47 (87.0) –
Bold italic significant results
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with positive lymph nodes suggests that tumor budding is a
poor prognostic feature of BC. The limited number of
patients and the fact that this is a retrospective study can be
regarded as disadvantage. However, the endpint of this
study was the lymph node status and not survival.
However, we did not find an association to tumor size or
T-category as in the study by Liang et al. Certainly, the
differences between the two studies could be related to the
manner in which tumor buds were investigated. For our
evaluation, we used IHC to better visualize hot-spots of
single tumor cells or small tumor clusters and we defined
tumor budding to be between 1 and 5 tumor cells and each
pathologist scored 10 HPF in SRS. In the Liang study,
H&E was predominately used for scoring and tumor buds
were defined as 1–4 tumor cells. Pathologists scored 5
‘‘hot-spot’’ loci. In addition, we investigated ITB, which
was not previously described.
Interestingly, in colon cancer, a cut-off of[=10 buds is
proposed for high tumor budding [14]. In BC fewer tumor
buds are required in SRS to stratify BC with adverse tumor
features. The colon mucosa is much more involved in
immune defense than breast tissue and for this reason may
require a higher budding load to have adverse prognostic
effects. Evaluating tumor budding in each tissue and spe-
cimen type separately will therefore be necessary to obtain
meaningful prognostic data.
Epithelial–mesenchymal transition (EMT), a feature of
metastatic cells, has previously been described in the
context of tumor budding [22] and could be consistent with
the observed association to both LVI and lymph node
positivity but requires further analysis. A recent report also
demonstrated that estrogen is involved in EMT in breast
cancer cell lines with stem cell properties [23] and it was
shown that estrogen is involved in disruption of tight-
junction and increased cell motility [24]. We suspect that
ER-positive tumors with high tumor budding may be un-
dergoing a high degree of EMT and therefore have more
metastatic potential. Further, the tumor center, which can
have fibrosis, may represent a more hypoxic environment
what might contribute to EMT transformation [25]. How-
ever, these hypotheses need further investigations.
In our study, we confirmed the presence of tumor bud-
ding in BC and its association to known poor prognostic
indicators such as lymphatic invasion and positive lymph
node status in univariate analysis in SRS. However, in-
formation on vascular invasion and lymph node status
would be more relevant in the preoperative setting for
therapeutic decisions. Therefore, we investigated tumor
budding on matching preoperative CBs for the first time in
BC. Since CB are randomly sampled and consist of smaller
pieces of tissue, tumor buds cannot be classified as PTB or
ITB and also require different scoring criteria. In CBs, we
identified a significant association of tumor buds with ve-
nous invasion, suggesting that CBs with high tumor bud-
ding might harbor a tumor cell population with an affinity
for vascular invasion. The significance of this finding needs
to befurther investigated. The lack of an association with
LVI or positive nodal status as is observed in SRSs with
high PTB could be explained if CB contain mostly ITB.
Another explanation might be that the random capturing of
tumor buds amidst a mix of PTB and ITB in CBs dilutes
correlations of LVI and positive nodal status.
We demonstrated for the first time in BC that budding
can be subdivided into ITB and PTB based on tumor lo-
calization, which may have disease implications. More
research is needed to better understand the biological and
clinical significance of ITB versus PTB in BC. Further, the
concordance of scoring between the pathologists is better
than the assessment of other tumor markers such as MIB1
[26]. Whether ITB could be used as an additional mor-
phological feature to stratify ER-positive or low prolif-
erative tumors (B15 %) into a high and low risk category
has to be investigated in a larger cohort. In addition, future
studies should incorporate MIB1 analysis on whole tissue
sections to bypass the reported caveat of obtaining sig-
nificantly lower proliferation indices when using TMAs
[27].
The evaluation of one tissue slide may not be ideal
disadvantage, however, most tumor markers are evaluated
on a single CB slide randomly selected from the tumor
mass and with much less tumor content. Still however,
implementation of tumor budding into the diagnostic set-
ting requires further standardization to better define tumor
buds and establish scoring parameters and cut-off criteria
based on sensitivity and specificity. According to our data,
tumor budding is a histological feature in BC with asso-
ciation to a more aggressive tumor phenotype and which
may increase potential for metastasis. Our data demonstrate
the utility of tumor budding in BC to potentially enhance
prognostication in the clinic and warrants further
investigation.
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